{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.answeringMemberPrinted=Lord+O%27Shaughnessy&max-answer.questionFirstAnswered.=2017-07-31T13%3A38%3A56.527Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answer.answeringMemberPrinted=Lord+O%27Shaughnessy&max-answer.questionFirstAnswered.=2017-07-31T13%3A38%3A56.527Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_metadata=all&answer.answeringMemberPrinted=Lord+O%27Shaughnessy&max-answer.questionFirstAnswered.=2017-07-31T13%3A38%3A56.527Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&answer.answeringMemberPrinted=Lord+O%27Shaughnessy&max-answer.questionFirstAnswered.=2017-07-31T13%3A38%3A56.527Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.answeringMemberPrinted=Lord+O%27Shaughnessy&max-answer.questionFirstAnswered.=2017-07-31T13%3A38%3A56.527Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.answeringMemberPrinted=Lord+O%27Shaughnessy&max-answer.questionFirstAnswered.=2017-07-31T13%3A38%3A56.527Z", "items" : [{"_about" : "http://data.parliament.uk/resources/755110", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/755110/answer", "answerText" : {"_value" : "<p>Data on the number of BME patients being treated in locked rehabilitation wards in England is not collected centrally, though we would expect trusts to pay close attention to such data.<\/p><p> <\/p><p>The Government welcomes the findings of the Care Quality Commission\u2019s (CQC\u2019s) report and shares its concerns about inappropriate use of locked rehabilitation wards. The department will consider the implications in discussion with NHS England, NHS Improvement and the CQC.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
        , "dateOfAnswer" : {"_value" : "2017-07-31", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "HL1119"}
        , {"_value" : "HL1120"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2017-07-31T13:25:20.433Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2017-07-20", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Secure Psychiatric Units: Ethnic Groups"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "Her Majesty's Government, what data are collected regarding the number of BME patients in locked wards in England; and what plans they have to impose new requirements for the collection of such data.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/147", "label" : {"_value" : "Biography information for Lord Boateng"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Boateng"}
      ], "uin" : "HL1118"}
    , {"_about" : "http://data.parliament.uk/resources/755111", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/755111/answer", "answerText" : {"_value" : "<p>Data on the number of BME patients being treated in locked rehabilitation wards in England is not collected centrally, though we would expect trusts to pay close attention to such data.<\/p><p> <\/p><p>The Government welcomes the findings of the Care Quality Commission\u2019s (CQC\u2019s) report and shares its concerns about inappropriate use of locked rehabilitation wards. The department will consider the implications in discussion with NHS England, NHS Improvement and the CQC.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
        , "dateOfAnswer" : {"_value" : "2017-07-31", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "HL1118"}
        , {"_value" : "HL1120"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2017-07-31T13:25:20.527Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2017-07-20", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Secure Psychiatric Units: Ethnic Groups"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "Her Majesty's Government how many patients from BME backgrounds spent a period of their care in locked wards in England during each of the last three years for which figures are available.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/147", "label" : {"_value" : "Biography information for Lord Boateng"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Boateng"}
      ], "uin" : "HL1119"}
    , {"_about" : "http://data.parliament.uk/resources/755112", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/755112/answer", "answerText" : {"_value" : "<p>Data on the number of BME patients being treated in locked rehabilitation wards in England is not collected centrally, though we would expect trusts to pay close attention to such data.<\/p><p> <\/p><p>The Government welcomes the findings of the Care Quality Commission\u2019s (CQC\u2019s) report and shares its concerns about inappropriate use of locked rehabilitation wards. The department will consider the implications in discussion with NHS England, NHS Improvement and the CQC.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
        , "dateOfAnswer" : {"_value" : "2017-07-31", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "HL1118"}
        , {"_value" : "HL1119"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2017-07-31T13:25:20.59Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2017-07-20", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Secure Psychiatric Units: Ethnic Groups"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "Her Majesty's Government what conclusions they have drawn from the Care Quality Commission review The state of care in mental health services 2014 to 2017, published on 20 July, as to the numbers and experience of BME patients in locked wards across England.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/147", "label" : {"_value" : "Biography information for Lord Boateng"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Boateng"}
      ], "uin" : "HL1120"}
    , {"_about" : "http://data.parliament.uk/resources/755129", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/755129/answer", "answerText" : {"_value" : "<p>The focus of the inquiry will be on establishing the truth of what happened.<\/p><p> <\/p><p>Over the summer, the Government is consulting with those affected and key stakeholder groups to discuss the scope of the inquiry.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
        , "dateOfAnswer" : {"_value" : "2017-07-31", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2017-07-31T13:25:47.093Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2017-07-20", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Blood: Contamination"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "Her Majesty's Government whether the findings of the 2009 independent report by Lord Archer of Sandwell on NHS supplied contaminated blood and blood products will be taken into account by the contaminated blood inquiry announced on 11 July.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3573", "label" : {"_value" : "Biography information for Baroness Gould of Potternewton"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Baroness Gould of Potternewton"}
      ], "uin" : "HL1137"}
    , {"_about" : "http://data.parliament.uk/resources/753910", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/753910/answer", "answerText" : {"_value" : "<p>Cancer survival rates are at a record high and around 7,000 more people are surviving cancer after successful treatment on the National Health Service compared to three years ago. However, there is more that we can do. NHS England is leading the implementation of the recommendations of the independent Cancer Taskforce to save a further 30,000 lives by 2020.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
        , "dateOfAnswer" : {"_value" : "2017-07-31", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2017-07-31T13:27:52.883Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2017-07-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer: Mortality Rates"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "Her Majesty's Government what is their assessment of the findings by Integrating the Healthcare Enterprise in its report, Comparator report on patient access to cancer medicines in Europe Revisited, that UK five-year survival outcomes for cancer lag behind the European average for nine out of ten cancers.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2024", "label" : {"_value" : "Biography information for Lord Hunt of Kings Heath"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Hunt of Kings Heath"}
      ], "uin" : "HL1056"}
    , {"_about" : "http://data.parliament.uk/resources/753958", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/753958/answer", "answerText" : {"_value" : "<p>The Government is fully aware of the importance of molybdenum-99 and the reliance on this medical radioisotope for diagnostic procedures in the National Health Service. The United Kingdom\u2019s ability to import medical isotopes from Europe and the rest of the world will not be affected by withdrawal from Euratom. It is in everyone\u2019s interest to not disrupt the timely access of treatment to patients and to ensure that cross-border trade with the European Union and Euratom is as frictionless as possible.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
        , "dateOfAnswer" : {"_value" : "2017-07-31", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2017-07-31T13:38:56.527Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2017-07-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Radioisotopes: Imports"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "Her Majesty's Government (1) what assessment they have made of the potential impact of not reaching agreement with the EU by April 2019 on the supply of the radioisotope molybdenum-99 used to produce technetium-99m which is required for over 80 per cent of diagnostic medicine procedures in the UK; (2) what assessment they have made of the potential impact of delays or disruption to the supply of diagnostic medicine procedures that may result; and (3) what contingency plans they have put in place to mitigate such delays or disruption to that supply after Brexit.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4286", "label" : {"_value" : "Biography information for Lord Mendelsohn"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Mendelsohn"}
      ], "uin" : "HL1104"}
    , {"_about" : "http://data.parliament.uk/resources/752468", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/752468/answer", "answerText" : {"_value" : "<p>The drug cost to the National Health Service for a one year supply of Apomorphine for a patient with Parkinson's Disease is estimated to be in the region of £5,300 and £9,000, based on the usual daily dose of 3 \u2013 30mg. However, the maximum daily is 100mg, so the annual cost for some patient\u2019s treatment may be higher.<\/p><p>We have no estimate of the cost of manufacture. We are not aware of any particular issues relating to the manufacture of this drug. Pharmaceutical companies participate in either the voluntary pharmaceutical price regulation scheme (PPRS) or the statutory medicines price regulation scheme, both of which regulate the cost of medicines to the NHS. Products covered by the statutory scheme are subject to a 15% cut to their list price. Companies in the PPRS pay a percentage of sales to the Government when growth in NHS spending on medicines exceeds an agreed level. NHS purchasers may also negotiate discounts with pharmaceutical companies in addition to national price regulation.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
        , "dateOfAnswer" : {"_value" : "2017-07-19", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2017-07-19T15:12:09.617Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2017-07-17", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Parkinson's Disease: Drugs"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "Her Majesty's Government how much the NHS pays for a one year supply of Apomorphine for a patient with Parkinson's Disease; how much they estimate it costs to manufacture a year's supply of that drug; what assessment they have made of the difficulties of manufacturing Apomorphine to clinical standards; and whether they intend to take any steps to reduce the cost of that drug to the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1879", "label" : {"_value" : "Biography information for Lord Lucas"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Lucas"}
      ], "uin" : "HL914"}
    , {"_about" : "http://data.parliament.uk/resources/751964", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/751964/answer", "answerText" : {"_value" : "<p>The Health Premium Incentive Scheme was a pilot exercise carried out in 2014/15. The Government currently has no plans to implement a similar scheme.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
        , "dateOfAnswer" : {"_value" : "2017-07-19", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2017-07-19T15:06:37.503Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2017-07-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Airports: Air Pollution"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "Her Majesty's Government whether they have abandoned the Health Premium approach to funding part of the public health responsibilities of local government; and if so, why.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4181", "label" : {"_value" : "Biography information for Lord Beecham"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Beecham"}
      ], "uin" : "HL799"}
    , {"_about" : "http://data.parliament.uk/resources/751974", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/751974/answer", "answerText" : {"_value" : "<p>The Department does not hold this information.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
        , "dateOfAnswer" : {"_value" : "2017-07-19", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2017-07-19T11:03:13.337Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2017-07-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "European Committee for Standardization"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "Her Majesty's Government how much funding was allocated in 2016\u201317 to treat alcohol addiction in prisons.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4321", "label" : {"_value" : "Biography information for Lord Farmer"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Farmer"}
      ], "uin" : "HL809"}
    , {"_about" : "http://data.parliament.uk/resources/751979", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/751979/answer", "answerText" : {"_value" : "<p>The Department does not hold this information.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
        , "dateOfAnswer" : {"_value" : "2017-07-19", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2017-07-19T15:09:01.393Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2017-07-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Financial Services: Greater London"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "Her Majesty's Government how many individuals infected with blood contaminated by hepatitis C or HIV in the 1970s and 1980s remain alive.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4171", "label" : {"_value" : "Biography information for Lord Black of Brentwood"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Black of Brentwood"}
      ], "uin" : "HL814"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&answer.answeringMemberPrinted=Lord+O%27Shaughnessy&max-answer.questionFirstAnswered.=2017-07-31T13%3A38%3A56.527Z", "page" : 0, "startIndex" : 1, "totalResults" : 367, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}